Archive · 7 Sep 2025
Russian mRNA Cancer Vaccine Nears Approval After Successful Trials
Scientists in Russia have created a new cancer vaccine using mRNA technology called Enteromix.
The vaccine is designed to help the body fight cancer by training the immune system to identify and destroy cancer cells.
Tests showed that tumors shrank by 60-80%.
It worked well in tests and patients reported no serious side effects.
The vaccine is now awaiting official approval.
Researchers are also working on vaccines for other types of cancer, like glioblastoma and melanoma.
This new vaccine may help people by providing their bodies an army to fight off their cancers.
Enteromix, an mRNA cancer vaccine, completed successful clinical trials.
Trials showed high efficacy and safety with tumor shrinkage of 60-80%.
The vaccine targets and eliminates cancer cells by training the immune system.
Enteromix is awaiting final approval from Russia's Ministry of Health.
Researchers are also developing vaccines for glioblastoma and melanomas.
- Who
- Developed by Russia's National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB).
- What
- An mRNA-based cancer vaccine called Enteromix.
- When
- Preclinical studies and human trials completed; awaiting final approval.
- Where
- Russia
- Why
- To target and eliminate cancer cells with precision.
Potential Positive Outcomes
Concerns
Efficacy and Safety
Potential Positive Outcomes
Clinical trials showed high efficacy and no serious side effects, indicating a promising new treatment.
Concerns
No opposing views are mentioned.
- Vaccine Name
- Enteromix
- Technology
- mRNA
- Targets
- Colorectal cancer, glioblastoma, and melanoma
- Efficacy
- 60-80% tumor reduction
- Status
- Awaiting final approval
- Development Team
- National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology (EIMB)
Sources
Russia's Cancer Vaccine Enteromix Displays 100 Per Cent Efficacy In Clinical Trials
Cancer immunotherapy breakthrough: Russian vaccine Enteromix demonstrates 100 per cent efficacy in trials, ready for rollout
Russian scientists develop mRNA cancer vaccine Enteromix, initiates phase I clinical trial
Russian vaccine for colon cancer arriving soon; aces pre-clinical trials with high proven efficacy
